Health-related quality of life in patients with nail disorders

American Journal of Clinical Dermatology

Volumn 12, Issue 5, 2011, Pages 313-320

  Reich, Adam ^a   Szepietowski, Jacek C ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Antineoplastics; Nail disorders; Onychomycosis; Psoriasis; Quality of life

Indexed keywords

ANTIFUNGAL AGENT;

ARTHROPATHY; BURNING SENSATION; CELLULITIS; DISEASE DURATION; DISEASE SEVERITY; FINGERNAIL ONYCHOMYCOSIS; FUNCTIONAL DISEASE; HUMAN; HYPERKERATOSIS; NAIL COLOR DEFECT; NAIL DISEASE; ONYCHOLYSIS; ONYCHOMYCOSIS; PARESTHESIA; PERSONAL APPEARANCE; PRESSURE GRADIENT; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PSYCHOLOGICAL WELL BEING; QUALITY OF LIFE; REVIEW; SELF ESTEEM; SKIN DISCOMFORT; SKIN TINGLING; SOCIAL BEHAVIOR; TOENAIL ONYCHOMYCOSIS;

HUMANS; NAIL DISEASES; ONYCHOMYCOSIS; PSORIASIS; QUALITY OF LIFE; SELF CONCEPT;

EID: 80051727437     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11592120-000000000-00000     Document Type: Review

References (60)

1. Reich A, Szepietowski JC. Quality of life in toenail onychomycosis. In: Preedy VR, Watson RR, editors. Handbook of disease burdens and quality of life measures. New York (NY): Springer, 2010: 3837-50
2. Reich K. Approach to managing patients with nail psoriasis. J Eur Acad Dermatol Venereol 2009 Sep; 23 Suppl. 1: 15-21
3. Moss C, Wong A, Davies P. The Birmingham Epidermolysis Bullosa Severity score: development and validation. Br J Dermatol 2009 May; 160 (5): 1057-65
4. Szepietowski JC, Reich A, Garlowska E, et al. Factors influencing coexistence of toenail onychomycosis with tinea pedis and other dermatomycoses: a survey of 2761 patients. Arch Dermatol 2006 Oct; 142 (10): 1279-84 (Pubitemid 44583277)
5. Reich A, Schwartz RA, Szepietowski JC. Complications of superficial mycoses. In: Fratamico PM, Smith JL, Brogden KA, editors. Sequelae and long-term consequences of infectious diseases. Washington, DC: ASM Press, 2009: 407-13
6. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol 2007 Jul; 57 (1): 1-27 (Pubitemid 46899261)
7. Edwards F, de Berker D. Nail psoriasis: clinical presentation and best practice recommendations. Drugs 2009; 69 (17): 2351-61
8. Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis: clinically important, potentially treatable and often overlooked. Rheumatology (Oxford) 2004 Jun; 43 (6): 790-4 (Pubitemid 38807439)
9. Radtke MA, Langenbruch AK, Schäfer I, et al. Nail psoriasis as a severity indicator: results fromthe PsoReal study. Patient Relat Outcome Meas 2011; 2: 1-6
10. Baran R. The burden of nail psoriasis: an introduction. Dermatology 2010; 221 Suppl. 1: 1-5
11. Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg 2003 Jul-Aug; 7 (4): 317-21 (Pubitemid 37410452)
12. Lawry M. Biological therapy and nail psoriasis. Dermatol Ther 2007 Jan-Feb; 20 (1): 60-7 (Pubitemid 46568378)
13. Hussain W, Coulson I, Owen C. Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients. Clin Exp Dermatol 2008 Jul; 33 (4): 520-2 (Pubitemid 351832149)
14. Gupta AK, Cooper EA. Psoriatic nail disease: quality of life and treatment. J Cutan Med Surg 2009 Sep-Oct; 13 Suppl. 2: S102-6
15. de Jong EM, Seegers BA, Gulinck MK, et al. Psoriasis of the nails associated with disability in a large number of patients: results of a recent interview with 1,728 patients. Dermatology 1996; 193 (4): 300-3
16. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994 May; 19 (3): 210-6 (Pubitemid 24194579)
17. Augustin M, Reich K, Blome C, et al. Nail psoriasis in Germany: epidemiology and burden of disease. Br J Dermatol 2010 Sep; 163 (3): 580-5
18. Zimola̧g I, Reich A, Szepietowski JC. Influence of psoriasis on the ability to work [abstract no. OP76 plus oral presentation]. Acta Derm Venereol 2009 Sep; 89 (5): 575-6
19. Rams Ł, Reich A. Psoriasis in a view of patients: a questionnaire study [in Polish, abstract no. 113]. XIVth Nationwide Conference of Student Scientific Circles of Medical Universities; 2009 Apr 17-18; Wroclaw
20. Ortonne JP, Baran R, Corvest M, et al. Development and validation of nail psoriasis quality of life scale (NPQ10). J Eur Acad Dermatol Venereol 2010 Jan; 24 (1): 22-7
21. Warshaw EM, Foster JK, Cham PM, et al. NailQoL: a quality-of-life instrument for onychomycosis. Int J Dermatol 2007 Dec; 46 (12): 1279-86
22. Zdrojowy M, Szepietowski J, Zazulak N, et al. Quality of life in nail psoriasis [abstract no. OP25 plus oral presentation]. Acta Derm Venereol 2009 Sep; 89 (5): 561
23. Zdrojowy M, Szepietowski J, Zazulak N, et al. Creation and validation of Polish version of NailQoL questionnaire [abstract no. OP45]. Acta Derm Venereol 2009 Sep; 89 (5): 566-7
24. Rich P, Scher RK. Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003 Aug; 49 (2): 206-12 (Pubitemid 36951265)
25. Szepietowski JC, Reich A. Onychomycosis and quality of life. Eur Dermatol 2009; 4 (1): 85-7
26. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey. Br J Dermatol 1992 Feb; 126 Suppl. 39: 23-7
27. HeikkiläH, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995 Nov; 133 (5): 699-703
28. Gupta AK, Jain HC, Lynde CW, et al. Prevalence and epidemiology of unsuspected onychomycosis in patients visiting dermatologists? offices in Ontario, Canada: a multicenter survey of 2001 patients. Int J Dermatol 1997 Oct; 36 (10): 783-7 (Pubitemid 27497338)
29. Drake LA, Scher RK, Smith EB, et al. Effect of onychomycosis on quality of life. J Am Acad Dermatol 1998 May; 38 (5 Pt 1): 702-4 (Pubitemid 28213713)
30. Szepietowski JC, Reich A, Pacan P, et al. Evaluation of quality of life in patients with toenail onychomycosis by Polish version of an international onychomycosis-specific questionnaire. J Eur Acad Dermatol Venerol 2007 Apr; 21 (4): 491-6 (Pubitemid 46454902)
31. Elewski BE. The effect of toenail onychomycosis on patient quality of life. Int J Dermatol 1997 Oct; 36 (10): 754-6 (Pubitemid 27497329)
32. Arrese JE, Piérard-Franchimont C, Piérard GE. Fatal hyalohyphomycosis following Fusarium onychomycosis in an immunocompromised patient. Am J Dermatopathol 1996 Apr; 18 (2): 196-8 (Pubitemid 26127841)
33. Lubeck DP, Patrick DL, McNulty P, et al. Quality of life of persons with onychomycosis. Qual Life Res 1993 Oct; 2 (5): 341-8 (Pubitemid 24011486)
34. Lubeck DP. Measuring health-related quality of life in onychomycosis. J Am Acad Dermatol 1998 May; 38 (5 Pt 3): S64-8 (Pubitemid 28215626)
35. Stewart AL, Ware JE. Measuring functioning and well-being: the Medical Outcomes Study approach. Durham (NC): Duke University Press, 1992
36. Fleming JS, Courtney BE. The dimensionality of self-esteem II: hierarchical facet model for revised measurement scales. J Pers Soc Psychol 1984; 46: 404-21
37. Whittam LR, Hay RJ. The impact of onychomycosis on quality of life. Clin Exp Dermatol 1997 Mar; 22 (2): 87-9 (Pubitemid 27373679)
38. Drake L. Qualify of life issues with patients with fungal nail infections. AIDS Patient Care 1995; 9 Suppl. 1: S15-7 (Pubitemid 26047162)
39. Lubeck DP, Gause D, Schein JR, et al. A health-related quality of life measure for use in patients with onychomycosis: a validation study. Qual Life Res 1999; 8 (1-2): 121-9 (Pubitemid 29362753)
40. Lubeck DP, Schein JR, Gause D, et al. Health-related quality of life in patients with toenail onychomycosis: data from 9-month observational study. J Clin Outcomes Manage 1999; 6: 37-42
41. Drake LA, Patrick DL, Fleckman P, et al. The impact of onychomycosis on quality of life: development of an international onychomycosis-specific questionnaire to measure patient quality of life. J Am Acad Dermatol 1999 Aug; 41 (2 Pt 1): 189-96 (Pubitemid 29379702)
42. Ware Jr J, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996 Mar; 34 (3): 220-33 (Pubitemid 126433231)
43. Dupuy HJ. The Psychological General Well-Being index (PGWB). In: Wenger NK, Mattson ME, Furberg CD, et al., editors. Assessment of quality of life in clinical trials of cardiovascular therapies. New York (NY): Le Jacq Publishing, 1984: 170-83
44. Turner RR, Testa MA. Measuring the impact of onychomycosis on patient quality of life. Qual Life Res 2000 Feb; 9 (1): 39-53 (Pubitemid 30670648)
45. Firooz A, Khamesipour A, Dowlati Y. Itraconazole pulse therapy improves the quality of life of patients with toenail onychomycosis. J Dermatol Treat 2003 Jun; 14 (2): 95-8 (Pubitemid 36648699)
46. Potter LP, Mathias SD, Raut M, et al. The OnyCOE-t questionnaire: responsiveness and clinical meaningfulness of a patient-reported outcomes questionnaire for toenail onychomycosis. Health Qual Life Outcomes 2006 Aug; 4: 50
47. Chren MM, Lasek RJ, Flocke SA, et al. Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol 1997 Nov; 133 (11): 1433-40 (Pubitemid 27490569)
48. Szepietowski JC, Reich A, Woźniak M, et al. Evaluation of quality of life in patients with onychomycosis using the Polish version of Dermatology Life Quality Index. Mikol Lek 2006; 13 (3): 193-8 (Pubitemid 44520972)
49. Szepietowski JC, Reich A, Wesöowska-Szepietowska E, et al. Quality of life in patients suffering from seborrheic dermatitis: influence of age, gender and education level. Mycoses 2009; 52 (4): 357-63
50. Katsambas A, Abeck D, Haneke E, et al. The effects of foot disease on quality of life: results of the Achilles Project. J Eur Acad Dermatol Venereol 2005 Mar; 19 (2): 191-5 (Pubitemid 40450423)
51. Szepietowski JC, Reich A; for the National Quality of Life in Dermatology Group. Stigmatisation in onychomycosis patients: a population-based study. Mycoses 2008; 52 (4): 343-9
52. Kowalczuk-Zieleniec E, Nowicki E, Majkowicz M. Onychomycosis changes quality of life [abstract no. P23-20]. J Eur Acad Dermatol Venereol 2002; 16 Suppl. 1: 248
53. Millikan LE, Powell DW, Drake LA. Quality of life for patients with onychomycosis. Int J Dermatol 1999 Sep; 38 Suppl. 2: 13-6 (Pubitemid 29469841)
54. Lateur N. Onychomycosis: beyond cosmetic distress. J Cosmet Dermatol 2006 Jun; 5 (2): 171-7
55. Tabolli S, Alessandroni L, Gaido J, et al. Health-related quality of life and nail disorders. Acta Derm Venereol 2007; 87 (3): 255-9 (Pubitemid 47226895)
56. Gilbar P, Hain A, Peereboom VM. Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract 2009 Sep; 15 (3): 143-55
57. Hong J, Park SH, Choi SJ, et al. Nail toxicity after treatment with docetaxel: a prospective analysis in patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 2007 Jun; 37 (6): 424-8 (Pubitemid 47249478)
58. Winther D, Saunte DM, Knap M, et al. Nail changes due to docetaxel: a neglected side effect and nuisance for the patient. Support Care Cancer 2007 Oct; 15 (10): 1191-7 (Pubitemid 47459864)
59. van de Kerkhof PC, Pasch MC, Scher RK, et al. Brittle nail syndrome: a pathogenesis-based approach with a proposed grading system. J Am Acad Dermatol 2005 Oct; 53 (4): 644-51 (Pubitemid 41399933)
60. Scher RK. Brittle nails. Int J Dermatol 1989 Oct; 28 (8): 515-6 (Pubitemid 19256555)